Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioScore Inc.

This article was originally published in Start Up

Executive Summary

A great deal of occlusive disease cannot be treated with stents and conventional angioplasty balloons. Some 30% of lesions are complex and require special methods or tools because they're hard and calcified, because the lesions are ostial or located at bifurcations, because they're in vessels prone to elastic recoil, because disease is long and diffuse, or because they are otherwise unstentable. It is exactly this set of challenges that AngioScore has set out to address.

You may also be interested in...



Atherectomy Devices: At the Cutting Edge of Peripheral Vascular Disease

In the past, many medical device companies have seen PVD as a smaller offshoot of the coronary market and have sought to tap the opportunity primarily as a kind of commercial and technological second thought. Thus, they've largely tried to adapt devices developed for the coronary vasculature to peripheral applications-stents are the best example-only to fail, not because the market for PVD devices isn't there, but because significant differences between the anatomy of the peripheral and coronary vasculature mean that coronary devices don't always translate well to this new area. Now, though, as suggested by the success of FoxHollow, which recently went public, one of the most product areas for PVD may be a technology that has been around for a long time in coronary therapy but has gained a shaky reputation: atherectomy. New companies with interventional plaque clearing technologies-Cardiovascular Systems, Pathway Medical, and Minnow Medical-are thus targeting PVD first, coronary arteries, second.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel